- Home
- MKZR vs TCRT Comparison
MKZR vs TCRT Comparison
Compare MKZR & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKZR | TCRT |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 6.7M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | MKZR | TCRT |
|---|---|---|
| Price | $3.33 | $2.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.9K | ★ 15.2K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | N/A | $5,680,500.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $1.67 |
| 52 Week High | $6.99 | $5.48 |
Technical Indicators
Market Signals| Indicator | MKZR | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 37.42 | 41.77 |
| Support Level | $0.58 | $2.86 |
| Resistance Level | $4.03 | $2.89 |
| Average True Range (ATR) | 0.25 | 0.21 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 4.00 | 30.00 |
Price Performance
Historical ComparisonAbout MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.